Reduction in Acute Limb Ischemia with Rivaroxaban versus Placebo in Peripheral Artery Disease after Lower Extremity Revascularization: Insights from VOYAGER PAD

Conclusions: After LER for symptomatic PAD, ALI is frequent, particularly early after LER, and is associated with poor prognosis. Low-dose rivaroxaban plus aspirin reduces ALI after LER, including ALI events associated with the most severe outcomes. The benefit of rivaroxaban for ALI appears early, continues over time, and is consistent regardless of revascularization approach or clopidogrel use.PMID:34637332 | DOI:10.1161/CIRCULATIONAHA.121.055146

Source: Circulation - October 12, 2021 Category: Cardiology Authors: Connie N Hess E Sebastian Debus Mark R Nehler Sonia S Anand Manesh R Patel Michael Szarek Warren H Capell Judith Hsia Joshua A Beckman Marianne Brodmann Rafael Diaz Peter Habertheuer Nicholas J Leeper Richard J Powell Henrik Sillesen Eva Muehlhofer Scott Source Type: research